← All trials
NCT05043987
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2022
- Primary completion
- Feb 15, 2025
- Completion date
- Mar 15, 2025
- First posted
- Sep 14, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 72
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yiling Pharmaceutical Inc.Lead sponsor
- Yiling Pharmaceutical Inc.Study director
- Shijiazhuang Pharma Group (CSPC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.